On September 30, 2025 Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company reported having signed a license agreement for SunRock Biopharma’s SRB21, an HER3/HER2 antibody (Press release, Debiopharm, SEP 30, 2025, View Source [SID1234656361]). SunRock Biopharma is a Galician company supported by the regional government, Xunta de Galicia, through Xesgalicia, devoted to the development of antibodies against highly invasive tumors with an urgent clinical need in oncology. Debiopharm has exercised its option to license SunRock Biopharma’s bispecific antibody, which targets both HER2 and HER3 human epidermal growth factor receptors. This agreement, initially announced in 2023, will combine this antibody with Debiopharm’s proprietary MultiLINK Linker Technology to develop a new antibody-drug conjugate (ADC) under the name Debio 2512.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Debiopharm will leverage their "Trifecta" approach with this bispecific antibody to create a fit-for-purpose ADC using proprietary linkers and smart payload selection. Bispecific ADCs target multiple antigens simultaneously potentially offering higher efficacy and specificity while reducing off-target effects and overcoming resistance mechanisms. This dual-targeting strategy may allow for more potent delivery of cytotoxic payloads directly to cancer cells while sparing healthy tissues, offering breakthrough options for patients with resistant cancer types.
"Bi-specific ADCs hold significant promise as the next generation of cancer therapies," mentioned Bertrand Ducrey, CEO of Debiopharm. "We’re excited to confirm this licensing option as it allows us to apply our MultilinkTM Linker Technology to a dual-targeted design that could pave the way for breakthrough therapies in HER-driven cancers."
HER2-driven cancers are widely recognized as more aggressive forms of disease, marked by faster growth, earlier relapse, and a higher likelihood of treatment resistance.1 While recent therapies have provided meaningful advances, many patients ultimately develop resistance and metastasis, limiting the durability of response and long-term survival benefits. A bi-specific antibody targeting HER3 and HER2 represents a highly promising advancement for ADC development. By targeting simultaneously HER2 and HER3, this approach has the potential to overcome resistance mechanisms that limit current HER2-directed therapies.
"The licensing of SRB21 represents a significant milestone for SunRock Biopharma and a strong validation of our bi-specific antibodies platform," said Laureano Simón, CEO of SunRock Biopharma. "Through our collaboration with Debiopharm, we aim to accelerate the development of next-generation bi-specific ADCs, tailored to offer new hope to patients with HER2-resistant tumors."
"Patients fighting HER2-driven cancers require treatment approaches that can safely and effectively target and outsmart resistant or recurrent disease," explained Frederic Levy, CSO at Debiopharm. "The development of bi-specific ADCs targeting HER3 and HER2 in conjunction with our "Trifecta" approach represents a highly promising advancement in hard-to-treat cancers."